medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2025-360medsovet-9422Research ArticleКОСМЕТОЛОГИЯCOSMETOLOGYГипергликемия в фокусе профилактики возрастных изменений кожиHyperglycemia in the focus of prevention of age-related skin changeshttps://orcid.org/0000-0002-7865-486XШперлингН. В.ShperlingN. V.

Шперлинг Наталья Владимировна - д.м.н., профессор кафедры клинической медицины.

198095, Санкт-Петербург, ул. Калинина, д. 8, корп. 2а

Natalia V. Shperling - Dr. Sci. (Med.), Professor, Professor of Department of Clinical Medicine.

8, Bldg. 2а, Kalinina St., St Petersburg, 198095

shperling2@yandex.ruhttps://orcid.org/0000-0002-8509-1751ЧаплыгинА. В.ChaplyginA. V.

Чаплыгин Алексей Владимирович - к.м.н., доцент кафедры дерматовенерологии, Северо-Западный ГМУ имени И.И. Мечникова; главный врач, Клиника «МедЛегенда»; доцент кафедры дерматовенерологии, Санкт-Петербургский медико-социальный институт.

191015, Санкт-Петербург, ул. Кирочная, д. 41; 197373, Санкт-Петербург, Комендантский проспект, д. 56; 195271, Россия, Санкт-Петербург, Кондратьевский проспект, д. 72а

Aleхey V. Chaplygin - Cand. Sci. (Med.), Associate Professor of the Department of Dermatovenerology, North-Western SMU named after I.I. Mechnikov; Chief Medical Officer, MedLegenda Clinic; Associate Professor of the Department of Dermatovenerology, St Petersburg MSI.

41, Kirochnaya St., St Petersburg, 191015; 56, Komendantskiy Ave., St Petersburg, 197373; 72а, Kondratevskiy Ave., St Petersburg, 195271

av-chapl@yandex.ruЧаплыгинаН. В.ChaplyginaN. V.

Чаплыгина Наталья Васильевна - врач-дерматовенеролог, руководитель, Клиника «МедЛегенда».

197373, Санкт-Петербург, Комендантский проспект, д. 56

Natalia V. Chaplygina - Dermatovenerologist, Head, MedLegenda Clinic.

56, Komendantskiy Ave., St Petersburg, 197373

nataly0109@yandex.ruУниверситет «Реавиз»РоссияReaviz UniversityRussian FederationСеверо-Западный государственный медицинский университет имени И.И. Мечникова; Клиника «МедЛегенда»; Санкт-Петербургский медико-социальный институтРоссияNorth-Western State Medical University named after I.I. Mechnikov; MedLegenda Clinic; St Petersburg Medical and Social InstituteRussian FederationКлиника «МедЛегенда»РоссияMedLegenda ClinicRussian Federation202530092025014184192Copyright © Шперлинг Н.В., Чаплыгин А.В., Чаплыгина Н.В., 20252025Шперлинг Н.В., Чаплыгин А.В., Чаплыгина Н.В.Shperling N.V., Chaplygin A.V., Chaplygina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/9422

Нарушения синтеза и метаболизма коллагена лежат в основе патогенеза множества патологических состояний, в т. ч. наследственных (синдром Элерса – Данлоса, несовершенный остеогенез (болезнь «хрустального человека»), синдром Стиклера) и приобретенных (системная склеродермия, ревматоидный артрит, системная красная волчанка, дерматомиозит, цинга, печеночный фиброз (цирроз), легочный фиброз, кардиофиброз, почечный фиброз, келоидные (гипертрофические) рубцы, остеоартрит, остеопороз, буллезный эпидермолиз, хронои фотостарение кожи, онкологические заболевания и др.). Поддержание физиологического баланса процессов синтеза и деградации коллагена – важнейшее условие обеспечения структурной полноценности и функциональной активности соединительной ткани. В обзоре представлены систематизированные данные о роли коллагена в обеспечении структуры и функции тканей организма человека, в частности кожи, а также о коллаген-ассоциированных механизмах старения кожи в норме и при гипергликемических состояниях, сопровождающихся гликированием коллагена. Приведено фармакологическое обоснование применения агонистов рецепторов глюкагоноподобного пептида-1 (АрГПП-1) для профилактики возрастных изменений кожи. Понимание механизмов гликирования коллагена находится в фокусе антивозрастной медицины и критически важно для разработки стратегий замедления старения кожи. АрГПП-1 остаются объектом пристального внимания во всем мире. Представленные данные о положительном влиянии АрГПП-1 (Семавик®) на возможность контроля гипергликемии наглядно демонстрируют огромный потенциал указанных лекарственных средств в фокусе профилактики возрастных изменений кожи. Пострегистрационные исследования данной группы препаратов, особенно вновь появляющихся в арсенале лечащего врача, в частности Семавик®, позволят расширить спектр практических подходов к их дифференцированному применению и активному внедрению в клиническую практику.

Defects in collagen synthesis and metabolism underlie the pathogenesis of various pathological conditions, including hereditary disorders (Ehlers-Danlos syndrome, osteogenesis imperfecta (brittle bone disease), Stickler syndrome) and acquired diseases (systemic scleroderma, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, scurvy, liver fibrosis (cirrhosis), pulmonary fibrosis, cardiac fibrosis, renal fibrosis, keloid (hypertrophic) scars, osteoarthritis, osteoporosis, bullous epidermolysis, chronoand photoaging of the skin, cancer, etc.). Maintaining the physiological balance between the collagen synthesis and degradation processes is crucial for ensuring the structural integrity and functional activity of connective tissue. The review presents systematic data on the role of collagen in ensuring the structure and function of human body tissues, in particular, skin, as well as on collagen-associated mechanisms of skin aging in the nome and in hyperglycemic conditions accompanied by collagen glycation. The pharmacological justification of the use of glucagon-like peptide-1 (ArGPP-1) receptor agonists for the prevention of age-related skin changes is given. Understanding the mechanisms of collagen glycation is in the focus of anti-aging medicine and is critically important for developing strategies to slow skin aging. ArGPP-1 remains the object of close attention all over the world. The presented data on the positive effect of ArGPP-1 (Semavik®) on the ability to control hyperglycemia clearly demonstrate the enormous potential of these drugs in the prevention of age-related skin changes. Post-marketing studies of this group of drugs, especially newly appearing in the arsenal of the attending physician, in particular, Semavik®, will expand the range of practical approaches to their differentiated use and active implementation in clinical practice.

возрастные изменения кожиколлагенконечные продукты гликированиягипергликемияглюкагоноподобный пептидстарениеage-related skin changescollagenend products of glycationhyperglycemiaglucagon-like peptideagingReferencesPawlaczyk M, Lelonkiewicz M, Wieczorowski M. Age-dependent biomechanical properties of the skin. Poster Der Alergol. 2013;30(5):302–306. https://doi.org/10.5114/pdia.2013.38359.Pawlaczyk M, Lelonkiewicz M, Wieczorowski M. Age-dependent biomechanical properties of the skin. Poster Der Alergol. 2013;30(5):302–306. https://doi.org/10.5114/pdia.2013.38359.Solano F. Metabolism and Functions of Amino Acids in the Skin. Adv Exp Med Biol. 2020;1265:187–199. https://doi.org/10.1007/978-3-030-45328-2_11.Solano F. Metabolism and Functions of Amino Acids in the Skin. Adv Exp Med Biol. 2020;1265:187–199. https://doi.org/10.1007/978-3-030-45328-2_11.Борзых ОБ, Шнайдер НА, Карпова ЕИ, Петрова ММ, Демина ОМ, Насырова РФ. Синтез коллагена в коже, его функциональные и структурные особенности. Медицинский вестник Северного Кавказа. 2021;16(4):443–450. https://doi.org/10.14300/mnnc.2021.16108.Borzykh OB, Schneider NA, Karpova EI, Petrova MM, Demina OM, Nasyrova RF. Collagen synthesis in the skin, its functional and structural features. Medical News of North Caucasus. 2021;16(4):443–450. (In Russ.) https://doi.org/10.14300/mnnc.2021.16108.Mienaltowski MJ, Gonzales NL, Beall JM, Pechanec MY. Basic Structure, Physiology, and Biochemistry of Connective Tissues and Extracellular Matrix Collagens. In: Halper J (ed.) Progress in Heritable Soft Connective Tissue Diseases. Advances in Experimental Medicine and Biology, vol 1348. Springer, Cham; 2021, pp. 5–43. https://doi.org/10.1007/978-3-030-80614-9_2.Mienaltowski MJ, Gonzales NL, Beall JM, Pechanec MY. Basic Structure, Physiology, and Biochemistry of Connective Tissues and Extracellular Matrix Collagens. In: Halper J (ed.) Progress in Heritable Soft Connective Tissue Diseases. Advances in Experimental Medicine and Biology, vol 1348. Springer, Cham; 2021, pp. 5–43. https://doi.org/10.1007/978-3-030-80614-9_2.Seo BR, Chen X, Ling L, Song YH, Shimpi AA, Choi S et al. Collagen microarchitecture mechanically controls myofi broblast diff erentiation. Proc Natl Acad Sci USA. 2020;117(21):11387–11398. https://doi.org/10.1073/pnas.1919394117.Seo BR, Chen X, Ling L, Song YH, Shimpi AA, Choi S et al. Collagen microarchitecture mechanically controls myofi broblast diff erentiation. Proc Natl Acad Sci USA. 2020;117(21):11387–11398. https://doi.org/10.1073/pnas.1919394117.Fisher G. The pathophysiology of photoaging of the skin. Cutis. 2005;75(2):5–8. Available at: https://pubmed.ncbi.nlm.nih.gov/15773537.Fisher G. The pathophysiology of photoaging of the skin. Cutis. 2005;75(2):5–8. Available at: https://pubmed.ncbi.nlm.nih.gov/15773537.Parvez S, Kang M, Chung HS, Cho C, Hong MC, Shin MK, Bae H. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006;20(11):921–934. https://doi.org/10.1002/ptr.1954.Parvez S, Kang M, Chung HS, Cho C, Hong MC, Shin MK, Bae H. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006;20(11):921–934. https://doi.org/10.1002/ptr.1954.Cheng W, Yan-hua R, Fang-gang N, Guo-an Z. The content and ratio of type I and III collagen in skin differ with age and injury. African J Biotechnol. 2011;10(13):2524–2529.Cheng W, Yan-hua R, Fang-gang N, Guo-an Z. The content and ratio of type I and III collagen in skin differ with age and injury. African J Biotechnol. 2011;10(13):2524–2529.Lu Y, Zhang S, Wang Y, Ren X, Han J. Molecular mechanisms and clinical manifestations of rare genetic disorders associated with type I collagen. Intractable Rare Dis Res. 2019;8(2):98–107. https://doi.org/10.5582/irdr.2019.01064.Lu Y, Zhang S, Wang Y, Ren X, Han J. Molecular mechanisms and clinical manifestations of rare genetic disorders associated with type I collagen. Intractable Rare Dis Res. 2019;8(2):98–107. https://doi.org/10.5582/irdr.2019.01064.McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001;2:16. https://doi.org/10.1186/1471-2121-2-16.McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001;2:16. https://doi.org/10.1186/1471-2121-2-16.Roy B, Yuan L, Lee Y, Bharti A, Mitra A, Shivashankar GV. Fibroblast rejuvenation by mechanical reprogramming and rediff erentiation. Proc Natl Acad Sci USA. 2020;117(19):10131–10141. https://doi.org/10.1073/pnas.1911497117.Roy B, Yuan L, Lee Y, Bharti A, Mitra A, Shivashankar GV. Fibroblast rejuvenation by mechanical reprogramming and rediff erentiation. Proc Natl Acad Sci USA. 2020;117(19):10131–10141. https://doi.org/10.1073/pnas.1911497117.Кадурина ТИ. Наследственные коллагенопатии: клиника, диагностика, лечение, диспансеризация. СПб.: Невский диалект; 2000. 270 с.Кадурина ТИ. Наследственные коллагенопатии: клиника, диагностика, лечение, диспансеризация. СПб.: Невский диалект; 2000. 270 с.Zeng F, Harris RC. Epidermal growth factor, from gene organization to bedside. Semin Cell Dev Biol. 2014;28:2–11. https://doi.org/10.1016/j.semcdb.2014.01.011.Zeng F, Harris RC. Epidermal growth factor, from gene organization to bedside. Semin Cell Dev Biol. 2014;28:2–11. https://doi.org/10.1016/j.semcdb.2014.01.011.Целуйко СС, Малюк ЕА, Корнеева ЛС, Красавина НП. Морфофункциональная характеристика дермы кожи и ее изменения при старении (обзор литературы). Бюллетень физиологии и патологии дыхания. 2016;1(60):111–116. https://doi.org/10.12737/20130.Tseluiko SS, Malyuk EA, Korneeva LS, Krasavina NP. Morphofunctional parameters of skin dermis and its changes during aging (review). Bulletin Physiology and Pathology of Respiration. 2016;1(60):111–116. (In Russ.) https://doi.org/10.12737/20130.Потехина ЮП. Структура и функции коллагена. Российский остеопатический журнал. 2016;(1-2):87–99. https://doi.org/10.32885/2220-09752016-1-2-87-99.Potekhina Yu.P. Collagen Structure and Function. Russian Osteopathic Journal. 2016;(1-2):87–99. (In Russ.) https://doi.org/10.32885/2220-09752016-1-2-87-99.Merl-Pham J, Basak T, Knüppel L, Ramanujam D, Athanason M, Behr J et al. Quantitative proteomic profiling of extracellular matrix and site-specific collagen post-translational modifications in an in vitro model of lung fibrosis. Matrix Biol Plus. 2019;1:100005. https://doi.org/10.1016/j.mbplus.2019.04.002.Merl-Pham J, Basak T, Knüppel L, Ramanujam D, Athanason M, Behr J et al. Quantitative proteomic profiling of extracellular matrix and site-specific collagen post-translational modifications in an in vitro model of lung fibrosis. Matrix Biol Plus. 2019;1:100005. https://doi.org/10.1016/j.mbplus.2019.04.002.Rajan AM, Ma RC, Kocha KM, Zhang DJ, Huang P. Dual function of perivas-cular fibroblasts in vascular stabilization in zebrafish. PLoS Genet. 2020;16(10):e1008800. https://doi.org/10.1371/journal.pgen.1008800.Rajan AM, Ma RC, Kocha KM, Zhang DJ, Huang P. Dual function of perivas-cular fibroblasts in vascular stabilization in zebrafish. PLoS Genet. 2020;16(10):e1008800. https://doi.org/10.1371/journal.pgen.1008800.Walters BD, Stegemann JP. Strategies for directing the structure and function of three-dimensional collagen biomaterials across length scales. Acta Biomater. 2014;10(4):1488–1501. https://doi.org/10.1016/j.actbio.2013.08.038.Walters BD, Stegemann JP. Strategies for directing the structure and function of three-dimensional collagen biomaterials across length scales. Acta Biomater. 2014;10(4):1488–1501. https://doi.org/10.1016/j.actbio.2013.08.038.Капулер О, Сельская Б, Галеева А, Камилов Ф. Метаболизм коллагеновых волокон на фоне возрастных изменений. Врач. 2015;(8):64–69. Режим доступа: https://vrachjournal.ru/ru/25877305-2015-08-16.Kapuler O., Selskaya B., Galeeva A., Kamilov F. Metabolism of collagen fibers in the presence of age-related change. Vrach. 2015;(8):64–69. (In Russ.) Available at: https://vrachjournal.ru/ru/25877305-2015-08-16.Bella J, Hulmes DJ. Fibrillar Collagens. Subcell Biochem. 2017;82:457–490. https://doi.org/10.1007/978-3-319-49674-0_14.Bella J, Hulmes DJ. Fibrillar Collagens. Subcell Biochem. 2017;82:457–490. https://doi.org/10.1007/978-3-319-49674-0_14.Hoop CL, Zhu J, Nunes AM, Case DA, Baum J. Revealing Accessibility of Cryptic Protein Binding Sites within the Functional Collagen Fibril. Biomolecules. 2017;7(4):76. https://doi.org/10.3390/biom7040076.Hoop CL, Zhu J, Nunes AM, Case DA, Baum J. Revealing Accessibility of Cryptic Protein Binding Sites within the Functional Collagen Fibril. Biomolecules. 2017;7(4):76. https://doi.org/10.3390/biom7040076.Кубанова АА, Смольянников ВА, Служаева НГ. Старение кожи и возможности коррекции препаратом коллагена. Вестник дерматологии и венерологии. 2007;(5):70–73. Режим доступа: https://elibrary.ru/ijxhyn.Kubanova AA, Smolyannikov VA, Sluzhaeva NG. Skin aging and possibility of its correction by collagen preparation. Vestnik Dermatologii i Venerologii. 2007;(5):70–73. (In Russ.) Available at: https://elibrary.ru/ijxhyn.Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol. 2021;30(1):146–161. https://doi.org/10.1111/exd.14121.Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol. 2021;30(1):146–161. https://doi.org/10.1111/exd.14121.Avery N, Bailey A. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol. 2006;54(7):387–395. https://doi.org/10.1016/j.patbio.2006.07.005.Avery N, Bailey A. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol. 2006;54(7):387–395. https://doi.org/10.1016/j.patbio.2006.07.005.Verhaegen P, Zuijlen Р, Pennings N, Marle J, Niessen F, Horst C, Middelkoop E. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. Wound Repair Regen. 2009;17(5):649–656. https://doi.org/10.1111/j.1524475X.2009.00533.x.Verhaegen P, Zuijlen Р, Pennings N, Marle J, Niessen F, Horst C, Middelkoop E. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. Wound Repair Regen. 2009;17(5):649–656. https://doi.org/10.1111/j.1524475X.2009.00533.x.Miller E. Chemistry of collagens and their distribution. In: Piez KA, Raddi AH (eds.). Extracellular matrix. New York: Elsevier Science; 1984.Miller E. Chemistry of collagens and their distribution. In: Piez KA, Raddi AH (eds.). Extracellular matrix. New York: Elsevier Science; 1984.Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323–331. https://doi.org/10.1016/j.jconrel.2016.01.00712.Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323–331. https://doi.org/10.1016/j.jconrel.2016.01.007 12.Ozcelikkale A, Dutton JC, Grinnell F, Han B. Effects of dynamic matrix remodelling on en masse migration of fibroblasts on collagen matrices. J R Soc Interface. 2017;14(135):20170287. https://doi.org/10.1098/rsif.2017.0287.Ozcelikkale A, Dutton JC, Grinnell F, Han B. Effects of dynamic matrix remodelling on en masse migration of fibroblasts on collagen matrices. J R Soc Interface. 2017;14(135):20170287. https://doi.org/10.1098/rsif.2017.0287.Chanut-Delalande H, Bonod-Bidaud C, Cogne S, Malbouyres M, Ramirez F, Fichard A, Ruggiero F. Development of a functional skin matrix requires deposition of collagen V heterotrimers. Mol Cell Biol. 2004;24(13):6049–6057. https://doi.org/10.1128/MCB.24.13.6049-6057.2004.Chanut-Delalande H, Bonod-Bidaud C, Cogne S, Malbouyres M, Ramirez F, Fichard A, Ruggiero F. Development of a functional skin matrix requires deposition of collagen V heterotrimers. Mol Cell Biol. 2004;24(13):6049–6057. https://doi.org/10.1128/MCB.24.13.6049-6057.2004.Zhang Y, Tang Y, Quan X, Qiu L, Tian X, Liu Y, Gan L. Preliminary study of the ultrasonic measurement of thickness of skin in children. Zhonghua Shao Shang Za Zhi. 2007;23(5):352–355. Available at: https://pubmed.ncbi.nlm.nih.gov/18396762.Zhang Y, Tang Y, Quan X, Qiu L, Tian X, Liu Y, Gan L. Preliminary study of the ultrasonic measurement of thickness of skin in children. Zhonghua Shao Shang Za Zhi. 2007;23(5):352–355. Available at: https://pubmed.ncbi.nlm. nih.gov/18396762.Geesin J, Gordon J, Berg R. Regulation of collagen synthesis in human dermal fibroblasts by the sodium and magnesium salts of ascorbyl-2-phosphate. Skin Pharmacol. 1993;6(1):65–71. https://doi.org/10.1159/000211089.Geesin J, Gordon J, Berg R. Regulation of collagen synthesis in human dermal fibroblasts by the sodium and magnesium salts of ascorbyl-2-phosphate. Skin Pharmacol. 1993;6(1):65–71. https://doi.org/10.1159/000211089.Varani J, Dame MK, Rittie L, Fligiel SEG, Kang S, Fisher GJ, Voorhees JJ. Decreased Collagen Production in Chronologically Aged Skin. Roles of Age-Dependent Alteration in Fibroblast Function and Defective Mechanical Stimulation. Am J Pathol. 2006;168(6):1861–1868. https://doi.org/10.2353/ajpath.2006.051302.Varani J, Dame MK, Rittie L, Fligiel SEG, Kang S, Fisher GJ, Voorhees JJ. Decreased Collagen Production in Chronologically Aged Skin. Roles of Age-Dependent Alteration in Fibroblast Function and Defective Mechanical Stimulation. Am J Pathol. 2006;168(6):1861–1868. https://doi.org/10.2353/ajpath.2006.051302.Прилепская ВН, Назаренко ЕГ. Эстриол в терапии различных гинекологических заболеваний. Медицинский совет. 2017;(2):8–13. https://doi.org/10.21518/2079-701X-2017-2-8-13.Prilepskaya VN, Nazarenko EG. Estriol in therapy of various gynecological diseases. Meditsinskiy Sovet. 2017;(2):8–13. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-8-13.Talwar HS, Griffiths CE, Fisher GJ, Hamilton TA, Voorhees JJ. Reduced type I and type III procollagens in photodamaged adult human skin. J Invest Dermatol. 1995;105(2):285–290. https://doi.org/10.1111/1523-1747.ep12318471.Talwar HS, Griffiths CE, Fisher GJ, Hamilton TA, Voorhees JJ. Reduced type I and type III procollagens in photodamaged adult human skin. J Invest Dermatol. 1995;105(2):285–290. https://doi.org/10.1111/1523-1747.ep12318471.Lahmann C, Bergemann J, Harrison G, Young AR. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet. 2001;357(9260):935–936. https://doi.org/10.1016/S0140-6736(00)04220-3.Lahmann C, Bergemann J, Harrison G, Young AR. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet. 2001;357(9260):935–936. https://doi.org/10.1016/S0140-6736(00)04220-3.Mine S, Fortunel NO, Pageon H, Asselineau D. Aging Alters Functionally Human Dermal Papillary Fibroblasts but Not Reticular Fibroblasts: A New View of Skin Morphogenesis and Aging. PLoS ONE. 2008;3(12):e4066. https://doi.org/10.1371/journal.pone.0004066.Mine S, Fortunel NO, Pageon H, Asselineau D. Aging Alters Functionally Human Dermal Papillary Fibroblasts but Not Reticular Fibroblasts: A New View of Skin Morphogenesis and Aging. PLoS ONE. 2008;3(12):e4066. https://doi.org/10.1371/journal.pone.0004066.Robert L. An original approach to ageing: an appreciation of Fritz Verzar’s contribution in the light of the last 50 years of gerontological facts and thinking. Gerontology. 2006;52(5):268–274. https://doi.org/10.1159/000094607.Robert L. An original approach to ageing: an appreciation of Fritz Verzar’s contribution in the light of the last 50 years of gerontological facts and thinking. Gerontology. 2006;52(5):268–274. https://doi.org/10.1159/000094607.Park S, Jung WH, Pittman M, Chen J, Chen Y. The Effects of Stiffness, Fluid Viscosity, and Geometry of Microenvironment in Homeostasis, Aging, and Diseases: A Brief Review. J Biomech Eng. 2020;142(10):100804. https://doi.org/10.1115/1.4048110.Park S, Jung WH, Pittman M, Chen J, Chen Y. The Effects of Stiffness, Fluid Viscosity, and Geometry of Microenvironment in Homeostasis, Aging, and Diseases: A Brief Review. J Biomech Eng. 2020;142(10):100804. https://doi.org/10.1115/1.4048110.Mays P, Bishop J, Laurent G. Age-related changes in the proportion of types I and III collagen. Mech Ageing Dev. 1988;45(3):203–212. https://doi.org/10.1016/0047-6374(88)90002-4.Mays P, Bishop J, Laurent G. Age-related changes in the proportion of types I and III collagen. Mech Ageing Dev. 1988;45(3):203–212. https://doi.org/10.1016/0047-6374(88)90002-4.Ансари НА, Рашид З. Неферментативное гликирование белков: от диабета до рака. Биомедицинская химия. 2010;56(2):168–178. https://doi.org/10.18097/PBMC20105602168.Ansari NA, Rasheed Z. Non-enzymatic glycation of proteins: From diabetes to cancer. Biomeditsinskaya Khimiya. 2010;56(2):168–178. (In Russ.) https://doi.org/10.1134/S1990750809040027.Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–146. https://doi.org/10.1007/s001250051591.Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–146. https://doi.org/10.1007/s001250051591.Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 20031;419(1):89–96. https://doi.org/10.1016/j.abb.2003.08.016.Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 20031;419(1):89–96. https://doi.org/10.1016/j.abb.2003.08.016.Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR et al. The Maillard reaction in vivo. Z Ernahrungswiss. 1991;30(1):29–45. https://doi.org/10.1007/BF01910730.Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR et al. The Maillard reaction in vivo. Z Ernahrungswiss. 1991;30(1):29–45. https://doi.org/10.1007/BF01910730.Ansari NA, Ali R. Glycated lysine residues: a marker for non-enzymatic protein glycation in age-related diseases. Disease Markers. 2011;30(6):317–324. https://doi.org/10.3233/DMA-2011-0791.Ansari NA, Ali R. Glycated lysine residues: a marker for non-enzymatic protein glycation in age-related diseases. Disease Markers. 2011;30(6):317–324. https://doi.org/10.3233/DMA-2011-0791.Титов ВН, Хохлова НВ, Ширяева ЮК. Глюкоза, гликотоксины и продукты гликирования протеинов: роль в патогенезе. Клиническая медицина. 2013;(3):15–24. Режим доступа: https://cyberleninka.ru/article/n/glyukozaglikotoksiny-i-produkty-glikirovaniya-proteinov-rol-v-patogeneze.Titov VN, Khokhlova NV, Shiryaeva JK. Glucose, glycotoxins, and protein glycation products: the role in pathogenesis. Clinical Medicine (Russian Journal). 2013;(3):15–24. (In Russ.) Available at: https://cyberleninka.ru/article/n/glyukoza-glikotoksiny-i-produkty-glikirovaniya-proteinov-rolv-patogeneze.Glenn JV, Stitt AW. The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta. 2009;1790(10):1109–1116. https://doi.org/10.1016/j.bbagen.2009.04.016.Glenn JV, Stitt AW. The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta. 2009;1790(10):1109–1116. https://doi.org/10.1016/j.bbagen.2009.04.016.Semba RD, Ferrucci L, Sun K, Beck J, Dalal M, Varadhan R et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res. 2009;21(2):182–190. https://doi.org/10.1007/BF03325227.Semba RD, Ferrucci L, Sun K, Beck J, Dalal M, Varadhan R et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res. 2009;21(2):182–190. https://doi.org/10.1007/BF03325227.Krautwald M, Münch G. Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer’s disease? Exp Gerontol. 2010;45(10):744–751. https://doi.org/10.1016/j.exger.2010.03.001.Krautwald M, Münch G. Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer’s disease? Exp Gerontol. 2010;45(10):744–751. https://doi.org/10.1016/j.exger.2010.03.001.Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun. 2015;458(2):221–226. https://doi.org/10.1016/j.bbrc.2015.01.140.Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun. 2015;458(2):221–226. https://doi.org/10.1016/j.bbrc.2015.01.140.Гаврилова АО, Северина АС, Шамхалова МШ, Шестакова МВ. Роль конечных продуктов гликирования в патогенезе диабетической нефропатии. Сахарный диабет. 2021;24(5):461–469. https://doi.org/10.14341/DM12784.Gavrilova AO, Severina AS, Shamhalova MSh, Shestakova MV. The role of advanced glycation аnd products in patogenesis of diabetic nephropathy. Diabetes Mellitus. 2021;24(5):461–469. (In Russ.) https://doi.org/10.14341/DM12784.Yan HD, Li XZ, Xie JM, Li M. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. Chin Med J. 2007;120(9):787–793. https://doi.org/10.1097/00029330-200705010-00010.Yan HD, Li XZ, Xie JM, Li M. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. Chin Med J. 2007;120(9):787–793. https://doi.org/10.1097/00029330-200705010-00010.Gasparotto J, Girardi CS, Somensi N, Ribeiro CT, Moreira JCF, Michels M et al. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment. J Biol Chem. 2018;293(1):226–244. https://doi.org/10.1074/jbc.M117.786756.Gasparotto J, Girardi CS, Somensi N, Ribeiro CT, Moreira JCF, Michels M et al. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment. J Biol Chem. 2018;293(1):226–244. https://doi.org/10.1074/jbc.M117.786756.Шевцова АИ, Ткаченко ВА. Конечные продукты гликирования и их рецепторы при сердечно-сосудистых заболеваниях. Журнал Гродненского государственного медицинского университета. 2019;17(1):11–16. https://doi.org/10.25298/2221-8785-2019-17-1-11-16.Shevtsova AI, Tkachenko VA. End products of glycation and their receptors in cardiovascular diseases. Journal of the Grodno State Medical University. 2019;17(1):11–16. (In Russ.) https://doi.org/10.25298/2221-8785-2019-17-1-11-16.Menini S, Iacobini C, Ricci C, Fantauzzi CB, Salvi L, Pesce CM et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013;100(3):472–480. https://doi.org/10.1093/cvr/cvt206.Menini S, Iacobini C, Ricci C, Fantauzzi CB, Salvi L, Pesce CM et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013;100(3):472–480. https://doi.org/10.1093/cvr/cvt206.Ott C, Jacobs K, Haucke E, Navarrete SA, Grune T, Simm A. Role of advanced glycation end-products in cellular signaling. Redox Biol. 2014;9(2):411–429. https://doi.org/10.1016/j.redox.2013.12.016.Ott C, Jacobs K, Haucke E, Navarrete SA, Grune T, Simm A. Role of advanced glycation end-products in cellular signaling. Redox Biol. 2014;9(2):411–429. https://doi.org/10.1016/j.redox.2013.12.016.Xue J, Manigrasso M, Scalabrin M, Rai V, Reverdatto S, Burz DS et al. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure. 2016;24(9):1509–1522. https://doi.org/10.1016/j.str.2016.06.021.Xue J, Manigrasso M, Scalabrin M, Rai V, Reverdatto S, Burz DS et al. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling. Structure. 2016;24(9):1509–1522. https://doi.org/10.1016/j.str.2016.06.021.Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43(5):676–683. https://doi.org/10.2337/diab.43.5.676.Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43(5):676–683. https://doi.org/10.2337/diab.43.5.676.Elgawish A, Glomb M, Friedlander M, Monnier VM. Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem. 1996;271(22):12964–12971. https://doi.org/10.1074/jbc.271.22.12964.Elgawish A, Glomb M, Friedlander M, Monnier VM. Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem. 1996;271(22):12964–12971. https://doi.org/10.1074/jbc.271.22.12964.Ferreira AE, Ponces Freire AM, Voit EO. A quantitative model of the generation of N(epsilon)-(carboxymethyl)lysine in the Maillard reaction between collagen and glucose. Biochem J. 2003;376(1):109–121. https://doi.org/10.1042/BJ20030496.Ferreira AE, Ponces Freire AM, Voit EO. A quantitative model of the generation of N(epsilon)-(carboxymethyl)lysine in the Maillard reaction between collagen and glucose. Biochem J. 2003;376(1):109–121. https://doi.org/10.1042/BJ20030496.Бондарь ИА, Климонтов ВВ. Изменения метаболизма коллагена при диабетической нефропатии. Проблемы эндокринологии. 2005;51(2):23–28. https://doi.org/10.14341/probl200551223-28.Bondar IA, Klimontov VV. Collagen metabolic changes in diabetic nephropathy. Problemy Endokrinologii. 2005;51(2):23–28. (In Russ.) https://doi.org/10.14341/probl200551223-28.Каландия ММ, Токмакова АЮ, Галстян ГР. Роль конечных продуктов гликирования в развитии и прогрессировании диабетической нейроостеоартропатии. Проблемы эндокринологии. 2021;67(3):4–9. https://doi.org/10.14341/probl12778.Kalandia MM, Tokmakova AYu, Galstyan GR. The role of glycation end products in the development and progression of diabetic neuroosteoarthropathy. Problemy Endokrinologii. 2021;67(3):4–9. (In Russ.) https://doi.org/10.14341/probl12778.Бова АА, Громова ЮМ. Современные возможности и перспективы применения агонистов рецепторов глюкагоноподобного пептида-1 с позиции кардиолога. Медицинские новости. 2021;(7):6–12. Режим доступа: https://www.mednovosti.by/Journal.aspx?id=442/.Bova AA, Gromova YuM. Modern possibilities and prospects for the use of glucagon-like peptide-1 receptor agonists from the position of a cardiologist. Meditsinskie Novosti. 2021;(7):6–12. (In Russ.) Available at: https://www.mednovosti.by/Journal.aspx?id=442.Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9(1):46–52. https://doi.org/10.1016/S2213-8587(20)30343-0.Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9(1):46–52. https://doi.org/10.1016/S2213-8587(20)30343-0.Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6): 876–913. https://doi.org/10.1210/edrv.20.6.0385.Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6): 876–913. https://doi.org/10.1210/edrv.20.6.0385.Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ et al. Glucagonlike peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013. https://doi.org/10.1124/pr.115.011395.Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ et al. Glucagonlike peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013. https://doi.org/10.1124/pr.115.011395.Andersen A, Lund A, Knop FK, Vilsbоll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403. https://doi.org/10.1038/s41574-018-0016-2.Andersen A, Lund A, Knop FK, Vilsbоll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403. https://doi.org/10.1038/s41574-018-0016-2.Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–1048. https://doi.org/10.1210/en.2011-1499.Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–1048. https://doi.org/10.1210/en.2011-1499.Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes.Diabetes Spectr. 2017;30(3):202–210. https://doi.org/10.2337/ds16-0026.Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes.Diabetes Spectr. 2017;30(3):202–210. https://doi.org/10.2337/ds16-0026.Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–1565. https://doi.org/10.2337/db10-0474.Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–1565. https://doi.org/10.2337/db10-0474.Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. https://doi.org/10.1038/nrendo.2012.140.Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. https://doi.org/10.1038/nrendo.2012.140.DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr. 2014;27(2):100–112. https://doi.org/10.2337/diaspect.27.2.100.DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr. 2014;27(2):100–112. https://doi.org/10.2337/diaspect.27.2.100.Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):211–134. https://doi.org/10.1530/EJE-19-0566.Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):211–134. https://doi.org/10.1530/EJE-19-0566.Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10(1):5–19. https://doi.org/10.1007/s13300-018-0535-9.Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10(1):5–19. https://doi.org/10.1007/s13300-018-0535-9.Miñambres I, Pérez A. Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? Diabetol Metab Syndr. 2017;9:6. https://doi.org/10.1186/s13098-017-0204-6.Miñambres I, Pérez A. Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? Diabetol Metab Syndr. 2017;9:6. https://doi.org/10.1186/s13098-017-0204-6.Lyseng-Williamson KA. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39(8):805–819. https://doi.org/10.1007/s40261-019-00826-0.Lyseng-Williamson KA. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39(8):805–819. https://doi.org/10.1007/s40261-019-00826-0.George C, Byun A, Howard-Thompson A. New injectable agents for the treatment of type 2 diabetes part 2-glucagon-like peptide-1 (GLP-1) agonists. Am J Med. 2018;131(11):1304–1306. https://doi.org/10.1016/j.amjmed.2018.05.043.George C, Byun A, Howard-Thompson A. New injectable agents for the treatment of type 2 diabetes part 2-glucagon-like peptide-1 (GLP-1) agonists. Am J Med. 2018;131(11):1304–1306. https://doi.org/10.1016/j.amjmed.2018.05.043.Аметов АС, Невольникова АО, Тертычная ЕА. Возможности агонистов рецепторов глюкагоноподобного пептида-1 в снижении сердечно-сосудистого риска у пациентов с сахарным диабетом типа 2: что нового? Эндокринология: новости, мнения, обучение. 2019;28(3):44–53. https://doi.org/10.24411/2304-9529-2019-13005.Ametov AS, Nevolnikova AO, Tertychnaya EA. The advantage of using complex therapy for diabetic polyneuropathy in patients with type 2 diabetes mellitus. Endocrinology: News, Opinions, Training. 2019;28(3):44–53. (In Russ.) https://doi.org/10.24411/2304-9529-2019-13005.Анциферов МБ, Котешкова ОМ. Значение и место аналога глюкагоноподобного пептида-1 лираглутида в новой парадигме лечения сахарного диабета 2-го типа. Лечебное дело. 2018;(2):50–58. https://doi.org/10.24411/2071-53152018-12002.Antsiferov MB, Koteshkova OM. The significance and place of the glucagonlike peptide-1 analog liraglutide in the new paradigm of type 2 diabetes treatment. Lechebnoe Delo. 2018;(2):50–58. (In Russ.) https://doi.org/10.24411/2071-53152018-12002.Nauck MA, Meier JJ. Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(7):500–502. https://doi.org/10.1016/S2213-8587(19)30182-2.Nauck MA, Meier JJ. Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(7):500–502. https://doi.org/10.1016/S2213-8587(19)30182-2.Карпов ЮА, Старостина ЕГ. Семаглутид (Оземпик) с точки зрения эндокринолога и кардиолога: возможности аналогов глюкагоноподобного пептида-1 далеко не исчерпаны. Атмосфера. Новости кардиологии. 2019;(4):3–17. Режим доступа: http://www.atmosphere-ph.ru/modules.php?name=Magazines&sop=viewarticle&magid=4&issueid=482&artid=5986.Karpov YuA, Starostina EG. Semaglutide (Ozempik) from the point of view of an endocrinologist and cardiologist: the possibilities of analogues of glucagon-like peptide-1 are far from exhausted. Atmosphere. Cardiology News. 2019;(4):3–17. (In Russ.) Available at: http://www.atmosphere-ph.ru/modules.php?name=Magazines&sop=viewarticle&magid=4&issueid=482&artid=5986.Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. https://doi.org/10.1111/dom.12932.Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. https://doi.org/10.1111/dom.12932.Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193–206. https://doi.org/10.1016/S2213-8587(22)00008-0.Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193–206. https://doi.org/10.1016/S2213-8587(22)00008-0.Gou Y, Schwartz MW. How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs? J Clin Invest. 2023;133(19):e174597. https://doi.org/10.1172/JCI174597.Gou Y, Schwartz MW. How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs? J Clin Invest. 2023;133(19):e174597. https://doi.org/10.1172/JCI174597.Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radical Research. 2013;47(1):3–27. https://doi.org/10.3109/10715762.2013.815348.Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radical Research. 2013;47(1):3–27. https://doi.org/10.3109/10715762.2013.815348.Lingelbach LB, Mitchell AE, Rucker RB, McDonald RB. Accumulation of advanced glycation end-products in aging male Fischer 344 rats during long-term feeding of various dietary carbohydrates. J Nutr. 2000;130(5):1247–1255. https://doi.org/10.1093/jn/130.5.1247.Lingelbach LB, Mitchell AE, Rucker RB, McDonald RB. Accumulation of advanced glycation end-products in aging male Fischer 344 rats during long-term feeding of various dietary carbohydrates. J Nutr. 2000;130(5):1247–1255. https://doi.org/10.1093/jn/130.5.1247.Petrica L, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Vlad D et al. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study. J Diabetes Complications. 2015;29(2):230–237. https://doi.org/10.1016/j.jdiacomp.2014.11.014.Petrica L, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Vlad D et al. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study. J Diabetes Complications. 2015;29(2):230–237. https://doi.org/10.1016/j.jdiacomp.2014.11.014.Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Amino Acids. 2017;49(9):1535–1541. https://doi.org/10.1007/s00726-017-2464-8.Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Amino Acids. 2017;49(9):1535–1541. https://doi.org/10.1007/s00726-017-2464-8.Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end-products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci. 2012;317(1-2):1–5. https://doi.org/10.1016/j.jns.2012.02.018.Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end-products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci. 2012;317(1-2):1–5. https://doi.org/10.1016/j.jns.2012.02.018.Садыков РФ, Пак Х, Ким Ю, Ли С, Ха С, Ли С, О М. Конечные продукты гликации – маркеры старения и развития возраст-ассоциированных заболеваний. В чем причина и можно ли с этим бороться? Проблемы геронауки. 2023;(4):254–256. Режим доступа: https://www.geronauka.com/jour/article/view/48.Sadykov RF, Park H, Kim Y, Lee S, Ha S, Lee S, Oh M. Glycation End Products: Markers of Ageing and Age-Related Diseases. What is the Cause and Can It Be Controlled? Problems of Geroscience. 2023;(4):254–256. (In Russ.) Available at: https://www.geronauka.com/jour/article/view/48.Li X, Zheng T, Sang S, Lv L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. J Agric Food Chem. 2014;62(50):12152–12158. https://doi.org/10.1021/jf504132x.Li X, Zheng T, Sang S, Lv L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. J Agric Food Chem. 2014;62(50):12152–12158. https://doi.org/10.1021/jf504132x.Спасов АА, Ращенко АИ. Терапевтический потенциал разрывателей поперечных сшивок гликированных белков. Вестник Волгоградского государственного медицинского университета. 2016;57(1):12–15. Режим доступа: https://journals.eco-vector.com/1994-9480/article/view/118919.Spasov AA, Rashchenko AI. Therapeutic potential of crosslink breakers. Journal of Volgograd State Medical University. 2016;57(1):12–15. (In Russ.) Available at: https://journals.eco-vector.com/1994-9480/article/view/118919.

The authors declare that there are no conflicts of interest present.